Glaucoma gene discovery by UI researchers

Article

The gene sFRPI plays a key role in glaucoma development, and researchers from the University of Iowa (UI) have found that an over-expression of the gene raises fluid pressure in the eyes.

Iowa City, IA-The gene sFRPI plays a key role in glaucoma development, and researchers from the University of Iowa (UI) have found that an over-expression of the gene raises fluid pressure in the eyes.

The effects of excess sFRP1 protein were tested on mice and human donor eyes by researchers. They discovered that when there was an abnormality, the resulting proteins interfered with a singular pathway.

According to John Fingert, MD, PhD, a UI assistant professor of ophthalmology, the discovery could eventually facilitate early diagnosis and treatment of glaucoma.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.